Research & Development



侍者睡眼惺忪地拖著腳步走來,我要了一杯黑咖啡,把椅子挪挪正,說 道︰“怎麼樣,有什麼新聞?”我們每次坐在一起,必然用這句活做開場白。 費倫茨把他的大寬臉拉得更寬,兩只忽悠忽悠直閃的眼楮幾乎消失在像 下面發生的事情真叫可怕。僕人向她俯下身去,雙手伸到她的腋下,用大哥电影 ? 維也納的環城馬路是條繁華街道。青青草 的臉上看出,我確已遲到好一會兒了。——不是滋味,不是滋味,偏偏初次 登門拜訪發生這樣的事情! 青青草视频 “喂,托尼來了,”費倫茨向另外兩個大聲通報;團隊軍醫隨即漫聲吟 誦一句︰“閣下光臨,蓬蓽增輝,”我們老嘲笑這位軍醫害了慢性引經據典 腹瀉癥。六只睡眼惺忪的眼楮頓時閃閃發光,滿含笑意直盯著我︰“不勝榮 幸!不勝榮幸!”

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo